Bayesian Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Bayesian Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,700	Closed	-$21K	–	1093
2022 Q2	$21K	Buy	+10,700	New	+$23.3K	﹤0.01%	733

Other funds holding PRTK

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

Bayesian Capital Management's PRTK Position: Q3 2022 in Review

Bayesian Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2022, closing a stake of 10,700 shares — an estimated $21K sold.

Bayesian Capital Management first reported a position in PRTK in Q2 2022 and held it in 1 quarter. The position peaked at $21K in Q2 2022. 72 funds tracked by Wall St. Rank hold PRTK as of Q3 2022.

Bayesian Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Bayesian Capital Management sold 10,700 Paratek Pharmaceuticals, Inc. shares in Q3 2022, an estimated $21K.
Bayesian Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2022 and held it in 1 quarter.
Bayesian Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $21K in Q2 2022.
72 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2022.

Based on Bayesian Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.